Chapter 24 Formulation in Drug Discovery

Annual Reports in Medicinal Chemistry

Volumn 43, Issue , 2008, Pages 419-451

  Strickley, Robert G ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53049107059     PISSN: 00657743     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-7743(08)00024-9     Document Type: Review

References (25)

1. Venkatesh S., and Lipper R.A. Role of the Development Scientist in Compound Lead Selection and Optimization. J. Pharm. Sci. 89 (2000) 145
2. Fiese E.F.G. General Pharmaceutics - The New Physical Pharmacy. J. Pharm. Sci. 92 (2003) 1331
3. Curatolo W. Physical Chemical Properties of Oral Drug Candidates in the Discovery and Exploratory Development Settings. Pharm. Sci. Technol. Today 1 (1998) 387
4. Balbach S., and Korn C. Pharmaceutical Evaluation of Early Development Candidates "The 100 mg-Approach". Intl. J. Pharm. 275 (2004) 1
5. Avdeef A. Absorption and Drug Development: Solubility, Permeability and Charge State (2003), Wiley
6. Stella V.J., Martodihardjo S., Terada K., and Rao V.M. Some Relationships between the Physical Properties of Various 3-Acyloxymethyl Prodrugs of Phenytoin to Structure: Potential In Vivo Performance Implications. J. Pharm. Sci. 87 (1998) 1235
7. Hörter D., and Dressman J.B. Influence of Physicochemical Properties on Dissolution of Drugs in the Gastrointestinal Tract. Adv. Drug Deliv. Rev. 46 (2001) 75
8. C. A. Lipinski, Solubility in Water and DMSO: Issues and Potential Solutions, in "Pharmaceutical Profiling in Pharmaceutical Profiling Drug Discovery for Lead Selection" (eds R. T. Borchardt, E. H. Kerns, C. A. Lipinski, D. R. Thakker, and B. Wang), AAPS Press, 2004 pp. 93-126; Volume I in Biotechnology: Pharmaceutical Aspects (series eds R.T. Borchardt and C.R. Middaugh).
9. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Deliv. Rev. 23 (1997) 3
10. Lin J.H. Challenges in Drug Discovery: Lead Optimization and Prediction of Human Pharmacokinetics. In: Borchardt R.T., Kerns E.H., Lipinski C.A., Thakker D.R., and Wang B. (Eds). Pharmaceutical Profiling Drug Discovery for Lead Selection (2004), AAPS Press 293-325 Volume I in Biotechnology: Pharmaceutical Aspects (series eds R.T. Borchardt and C.R. Middaugh)
11. Yoshioka S., and Stella V.J. Stability of Drugs and Dosage Forms (2000), Kluwer Academic
12. V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag and J. W. Tilley (eds), Prodrugs: Challenges and Rewards, Part 1, Volume V in Biotechnology: Pharmaceutical Aspects, 2007 (series eds R. T. Borchardt and C. R. Middaugh).
13. V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag and J. W. Tilley (eds), Prodrugs: Challenges and Rewards, Part 2, Volume V in Biotechnology: Pharmaceutical Aspects, 2007 (series eds R. T. Borchardt and C. R. Middaugh).
14. Stella V.J. Prodrug Strategies for Improving Drug-Like Properties. In: Borchardt R.T., Kerns E.H., Hageman M.J., Thakker D.R., and Stevens J.L. (Eds). Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (2006), AAPS Press 221-242 Volume IV in Biotechnology: Pharmaceutical Aspects (series eds R.T. Borchardt and C.R. Middaugh)
15. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts, Properties, Selection, and Use (2002), Verlag Helvetica Chimica Acts, Zurich
16. Strickley R.G. Solubilizing Excipients in Oral and Injectable Formulations. Pharm. Res. 21 2 (2004) 201-230
17. Strickley R.G., and Oliyai R. Solubilizing Vehicles for Oral Formulation Development in Solvent Systems and Their Selection. In: Augustijns P., and Brewster M.E. (Eds). Pharmaceutics and Biopharmaceutics (2007), AAPS Press, UK 257-308 Volume VI in Biotechnology: Pharmaceutical Aspects (series eds R.T. Borchardt and C.R. Middaugh)
18. Pole D.L. Physical and Biological Considerations for the Use of Nonaqueous Solvents in Oral Bioavailability Enhancement. J. Pharm. Sci. 97 (2008) 1071
19. Strickley R.G. Parenteral Formulations of Small Molecules Therapeutics Marketed in the United States (1999) - Part I. PDA J. Pharm. Sci. Technol. 53 6 (1999) 324-349
20. R. G. Strickley, L. Liu and P. Lapresca, Preclinical Parenteral and Oral Formulations of Water Insoluble Molecules, ISSX Meeting, Nashville, TN (USA), Abstract # 291, 1999.
21. Aungst B.J., Nguyen N.H., Taylor N.J., and Bindra D.S. Formulation and Food Effect on the Oral Absorption of a Poorly Water Soluble, Highly Permeable Antiretroviral Agent. J. Pharm. Sci. 91 (2002) 1391-1395
22. In: Hauss D.J. (Ed). Oral Lipid-Based Formulations, Enhancing the Bioavailability of Poorly Water-Soluble Drugs (2007), Informa Healthcare
23. In: Podczeck F., and Jones B.E. (Eds). Pharmaceutical Capsules (2004), Pharmaceutical Press
24. Gad S.C., Cassidy C.D., Aubert N., Spainhour B., and Robbe H. Nonclinical Vehicle Use in Studies by Multiple Routes in Multiple Species. International Journal of Toxicology 25 (2006) 499-512
25. Lamarre D. An NS3 Protease Inhibitor with Antiviral Effects in Humams Infected with Hepatitis C Virus. Nature 426 (2003) 186-189